Japanese pharmaceutical company Toregem Biopharma says it has developed a new antibody drug that stops proteins in the mouth responsible for suppressing tooth growth.
The company is now planning to kick off human clinical trials in July 2024 and, depending on the results, eventually bring the drug to market by 2030, the"[Our] final goal is to offer advanced and scientifically driven clinical solution for the growth of teeth derived from their own tissues," Toregem's president Honoka Kiso wrote on theThe drug works by inhibiting a gene called USAG-1, which is responsible for stopping "tooth buds," which most people have, from ever...
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: